What is the address of CARDIOPERF?

The registered office of CARDIOPERF is located at Kleetboslaan 20, 1650 Beersel.

Is CARDIOPERF still active?

Yes. According to the CBE (31 October 2026) CARDIOPERF is active, legal situation “Normale toestand”, started on 8 March 2013.

Is CARDIOPERF registered on Peppol?

Yes, CARDIOPERF is registered on the Peppol network with ID 0208:0521874648.

What is the enterprise number of CARDIOPERF?

The enterprise number of CARDIOPERF is BE0521874648.

When was CARDIOPERF founded?

CARDIOPERF was founded on 8 March 2013.

Who are the directors of CARDIOPERF?

According to the 2025 annual accounts, the directors of CARDIOPERF are: Xavier Bechtold.

Is CARDIOPERF a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 March 2013; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CARDIOPERF make in 2025?

CARDIOPERF posted a profit after taxes of € 26,543 in financial year 2025.

What is the revenue of CARDIOPERF?

As a small company, CARDIOPERF is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 26,785.

CARDIOPERF (Private Limited) - Beersel - BE0521874648

Dossier CARDIOPERF, printed on 31 October 2026 from databakkes.be/en/0521874648/cardioperf. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CARDIOPERF from Beersel, company number BE0521874648, closed financial year 2025 with a result of € 26,543 after tax. For that financial year CARDIOPERF recorded a gross margin of € 26,785 and equity of € 169,270. Compared with financial year 2024, the result moved from € 15,714 to € 26,543. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Growing

€ 169,270

▲ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 26,543

▲ 69% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 32,545

▲ 198% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 163,070.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,149

▲ 58% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 19,338

▼ 4% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 21,829 Gross margin 2022: € 21,829 First fiscal year in the series	€ 31,574 Gross margin 2023: € 31,574 ▲ 45% vs 2022 (€ 21,829) Favourable step	€ 20,256 Gross margin 2024: € 20,256 ▼ 36% vs 2023 (€ 31,574) Unfavourable step	€ 26,785 Gross margin 2025: € 26,785 ▲ 32% vs 2024 (€ 20,256) Favourable step	▲ 32%
Profit after taxes	€ 10,739 Profit after taxes 2022: € 10,739 First fiscal year in the series	€ 22,885 Profit after taxes 2023: € 22,885 ▲ 113% vs 2022 (€ 10,739) Favourable step	€ 15,714 Profit after taxes 2024: € 15,714 ▼ 31% vs 2023 (€ 22,885) Unfavourable step	€ 26,543 Profit after taxes 2025: € 26,543 ▲ 69% vs 2024 (€ 15,714) Favourable step	▲ 69%
Equity	€ 104,129 Equity 2022: € 104,129 First fiscal year in the series	€ 127,014 Equity 2023: € 127,014 ▲ 22% vs 2022 (€ 104,129) Favourable step	€ 142,727 Equity 2024: € 142,727 ▲ 12% vs 2023 (€ 127,014) Favourable step	€ 169,270 Equity 2025: € 169,270 ▲ 19% vs 2024 (€ 142,727) Favourable step	▲ 19%
Total debts	€ 15,069 Total debts 2022: € 15,069 First fiscal year in the series	€ 20,152 Total debts 2023: € 20,152 ▲ 34% vs 2022 (€ 15,069) Unfavourable step	€ 20,787 Total debts 2024: € 20,787 ▲ 3% vs 2023 (€ 20,152) Unfavourable step	€ 20,486 Total debts 2025: € 20,486 ▼ 1% vs 2024 (€ 20,787) Favourable step	▼ 1%
Cash	€ 6,472 Cash 2022: € 6,472 First fiscal year in the series	€ 4,749 Cash 2023: € 4,749 ▼ 27% vs 2022 (€ 6,472) Unfavourable step	€ 10,926 Cash 2024: € 10,926 ▲ 130% vs 2023 (€ 4,749) Favourable step	€ 32,545 Cash 2025: € 32,545 ▲ 198% vs 2024 (€ 10,926) Favourable step	▲ 198%
Retained profit	€ 97,929 Retained profit 2022: € 97,929 First fiscal year in the series	€ 120,814 Retained profit 2023: € 120,814 ▲ 23% vs 2022 (€ 97,929) Favourable step	€ 136,527 Retained profit 2024: € 136,527 ▲ 13% vs 2023 (€ 120,814) Favourable step	€ 163,070 Retained profit 2025: € 163,070 ▲ 19% vs 2024 (€ 136,527) Favourable step	▲ 19%
Balance sheet total	€ 119,197 Balance sheet total 2022: € 119,197 First fiscal year in the series	€ 147,165 Balance sheet total 2023: € 147,165 ▲ 23% vs 2022 (€ 119,197) Unchanged	€ 163,514 Balance sheet total 2024: € 163,514 ▲ 11% vs 2023 (€ 147,165) Unchanged	€ 189,756 Balance sheet total 2025: € 189,756 ▲ 16% vs 2024 (€ 163,514) Unchanged	▲ 16%

Key figures of CARDIOPERF, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CARDIOPERF?

What happened at CARDIOPERF in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: profit of € 26,543 (▲ 69% vs 2024). filed late Source: NBB ↗
Mar 8, 2013 New establishment in Beersel. KBO
Mar 8, 2013 Start of the company according to the CBE. KBO
2013 Xavier Bechtold became a director. NBB

In short

From € 10,739 profit in 2022 to € 26,543 profit in 2025.

Paid € 38,576 in corporate taxes since 2022.

Best year ever: 2025, with € 26,543 profit.

Original PDFs at the National Bank ↗

Management

Xavier Bechtold

CARDIOPERF

PERFUSION EXPERTS

Behind CARDIOPERF is Xavier Bechtold. Xavier Bechtold is also behind PERFUSION EXPERTS.

Directors

According to the 2025 annual accounts

Xavier Bechtold

Director

Also active at: PERFUSION EXPERTS

since 2013

Establishments

Establishment units

Physical locations of this company

Registered office

Kleetboslaan 20

1650 Beersel

2.218.874.604

Groenejagersstraat 25

1653 Beersel

Active since 8 March 2013

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0521.874.648
VAT number: BE 0521.874.648
Registered office: Kleetboslaan 20, 1650 Beersel
Names & denominations: CARDIOPERF
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 8 March 2013
Peppol: Active · Active since 24 Nov 2023

View on CBE Public ↗ Annual accounts (NBB) ↗